Innovent Bio pockets HK$2.4bn from top-up

Chinese biotechnology firm Innovent Biologics has raised HK$2.39bn ($304.3m) after selling a chunk of stock through a top-up placement.

  • By Jonathan Breen
  • 04 Oct 2019

The Hong Kong Stock Exchange-listed company hit the market on Thursday evening. Placing agents Goldman Sachs and Morgan Stanley launched an accelerated bookbuild for the transaction with a goal to place the stock with at least six investors.

The deal comprised 97m secondary shares, on offer at HK$24.30 ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Global Green Bonds

Rank Lead Manager Amount $b No of issues Share %
  • Last updated
  • Today
1 Bank of America Merrill Lynch 11.60 51 7.18%
2 Credit Agricole CIB 9.00 52 5.57%
3 BNP Paribas 8.69 53 5.38%
4 HSBC 8.20 63 5.08%
5 Citi 7.70 48 4.76%